Clinical Trials Browser

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Adenoid Cystic, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT03951831 2025-04-25

REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer

Phase 2 Active not recruiting

26 enrolled

Genitourinary

Neoplasms, Prostatic Neoplasms

NCT06864533 2025-04-24

PKUFH-GS5

Phase NA Recruiting

315 enrolled

Genitourinary

Prostatic Neoplasms

NCT03764540 2025-04-13

CABPOSTAAT

Phase 2 Terminated

57 enrolled

Genitourinary

Prostatic Neoplasms

NCT02288247 2025-04-08

PRESIDE

Phase 3 Completed

688 enrolled 13 charts

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT05676203 2025-02-17

ARASAFE

Phase 3 Active not recruiting

250 enrolled

Genitourinary

Prostatic Neoplasms

NCT05348577 2025-01-27

CAPItello280

Phase 3 Active not recruiting

1,035 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT04812366 2024-12-16

GUNS

Phase 2 Recruiting

315 enrolled

Genitourinary

Prostatic Neoplasms

NCT02009449 2024-11-15

IVY

Phase 1 Completed

353 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT01957436 2024-11-12

PEACE1

Phase 3 Active not recruiting

1,173 enrolled

Genitourinary

Neoplasms, Prostatic Neoplasms

NCT05156905 2024-10-09

Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer

Phase 1 Terminated

6 enrolled

Genitourinary

Prostatic Neoplasms

NCT03230734 2024-09-27

RAPSON

Phase 2 Active not recruiting

70 enrolled

Genitourinary

Prostatic Neoplasms

NCT02649855 2024-08-06

Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer

Phase 2 Completed

74 enrolled 15 charts

Genitourinary

Prostatic Neoplasms

NCT04907227 2024-07-12

KEYNOTE-921

Phase 3 Terminated

81 enrolled 19 charts

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

Clinical Trials

OPTION-DDR

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients

TRIPLE-SWITCH

MK-2400-001

A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

THUNDER

MEVPRO-1

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

rechARge

CheckMate 9KD

A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer

Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors

FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients

REINFORCE

Lutécio

A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer

CONVERT-HB1

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone

M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

KEYNOTE-921

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

HS-10502

CheckMate 7DX

PRESERVE-001

REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer

PKUFH-GS5

CABPOSTAAT

PRESIDE

ARASAFE

CAPItello280

GUNS

IVY

PEACE1

Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer

RAPSON

Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer

KEYNOTE-921